Comparative Analysis of Outcomes Among Patients Treated With Xeljanz vs Biologics

NCT03964649 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7308

Last updated 2021-06-02

Study results available
· View outcomes & findings →

Summary

To compare rheumatoid arthritis (RA) patient characteristics, adherence, and costs between patients treated with tofacitinib (IR, XR and combined groups) to patients treated with each of the bDMARDs.

Conditions

  • Arthritis, Rheumatoid

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
0 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2020-04-06
Completion
2020-04-06

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03964649 on ClinicalTrials.gov